# Does Kansas Medicaid Cover Wegovy? KanCare's Weight-Loss Rules for 2026

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-11-06

Canonical page: https://glpwatchdog.org/research/kansas-medicaid-glp1-coverage

> Kansas is one of the few states whose Medicaid program pays for GLP-1s to treat obesity. We set out the November 2026 KanCare criteria and drug list, renewal weight-loss targets, the sleep apnea and MASH routes, teen rules, plan fax numbers and appeals.

## Key points

- KanCare covers Wegovy, Zepbound and Foundayo for weight loss with prior authorization; all three are preferred on the November 2026 list.
- Adults qualify at a BMI of 30, or 27 with a listed condition; teenagers from 12 can get Wegovy at the 95th percentile.
- First approvals last 28 weeks; renewal needs 5% weight loss by week 12 or 10% by week 28.
- Separate criteria cover Zepbound for sleep apnea (AHI 15, BMI 30) and Wegovy for MASH (F2 or F3).
- Plan members appeal to the plan within 60 days, then can ask for a state fair hearing.

Yes. KanCare, the Kansas Medicaid program, pays for Wegovy, Zepbound and the Foundayo pill to treat obesity, with prior authorization. Adults qualify at a BMI of 30, or 27 if they also have a condition tied to weight, high blood pressure for example, and all three drugs are preferred on the state’s November 2026 drug list.[1][2] Separate criteria cover Zepbound for sleep apnea and Wegovy for the liver disease MASH.[4][5]

> **About this article.** On November 6, 2026 we read the Kansas Department of Health and Environment’s anti-obesity, sleep apnea and MASH criteria, its prior authorization form and its drug list updated November 1, 2026. Plans can apply a state change on a slightly different date, so ask yours which form it uses. To compare states, use the [state Medicaid GLP-1 checker](https://glpwatchdog.org/tools/state-medicaid-glp1-checker).

## Does KanCare cover Wegovy or Zepbound for weight loss?

It does, which sets Kansas apart. Under federal law a state may leave weight-loss drugs out of Medicaid, and most do.[15] The Kansas criteria instead list Saxenda, Foundayo, Wegovy, Wegovy HD and Zepbound as anti-obesity drugs that need prior authorization, and they cover older drugs such as phentermine and orlistat without one.[1] Our explainer on [why Medicaid treats Ozempic and Wegovy differently](https://glpwatchdog.org/research/does-medicaid-cover-ozempic-and-wegovy) covers the federal side.

The request has to show a baseline weight and BMI and a treatment plan that includes diet, activity and behavior changes.[1] Adults need a BMI of 30 or more, or 27 or more with at least one condition from the state’s list. That list is broad: prediabetes or type 2 diabetes, raised blood pressure or cholesterol, heart disease, fatty liver disease, polycystic ovary syndrome, sleep apnea, osteoarthritis and acid reflux all count.[1] The prescriber also has to start with a preferred drug unless the patient meets the state’s test for a non-preferred one.[1]

*KanCare anti-obesity GLP-1 rules from the KDHE criteria (last reviewed August 19, 2026, updated November 1, 2026) and drug list (November 1, 2026)*

| Drug | Drug list | Ages | Starting BMI for adults | First approval |
| --- | --- | --- | --- | --- |
| Zepbound | Preferred | 18 and older | 30, or 27 with a listed condition | 28 weeks |
| Wegovy (2.4 mg pen) | Preferred | 12 and older | 30, or 27 with a listed condition | 28 weeks |
| Wegovy HD (7.2 mg) or Wegovy tablets | Preferred | 18 and older | 30, or 27 with a listed condition | 28 weeks |
| Foundayo | Preferred | 18 and older | 30, or 27 with a listed condition | 28 weeks |
| Saxenda | Non-preferred | 12 and older | 40, after 3 months of lifestyle changes | 8 weeks |

Saxenda is the exception. It stays on the state’s list of “high-cost” agents, which carries a BMI line of 40 for adults, 3 months of lifestyle changes first, and a one-year wait after a failed drug. The criteria say that section does not apply to Zepbound (since April 1, 2024), Wegovy (since June 1, 2025) or Foundayo (since November 1, 2026).[1] Foundayo and Wegovy HD needed clinical prior authorization from October 19, 2026, and members already filling one of them at least 80% of the time could get a grandfathered approval.[7][12]

## How has KanCare changed since 2024?

The rules have loosened. In September 2024, a plan summary of the state criteria made Zepbound the preferred drug that adults had to try first, and held Wegovy and Saxenda to a BMI of 40.[8] Wegovy left that high bar in June 2025, the 7.2 mg Wegovy HD pen became a preferred drug on May 1, 2026, and the November 2026 drug list names Wegovy, Wegovy HD, Zepbound and Foundayo as preferred.[1][6][2] The Zepbound-first step is gone from the current criteria.

## What does a renewal take?

For Zepbound, Wegovy and Foundayo, the first approval lasts 28 weeks. To renew, an adult must have lost 5% of their starting weight by week 12, or 10% by week 28, and kept it off, while staying on the lifestyle plan. A teenager needs a drop of more than 4% in BMI.[1] The first renewal lasts 6 months and later ones 12 months.[1] Saxenda is renewed against its own weight-loss table, starting at 3% after 8 weeks for adults.[1] The dose must stay within the label’s limits, and for Wegovy and Saxenda the patient must be able to reach and hold the full maintenance dose.[1][13]

## Does KanCare cover Wegovy for heart disease?

Yes, through the same anti-obesity criteria. Heart disease is one of the listed conditions, so an adult with a past heart attack or stroke and a BMI of 27 or more meets the weight test.[1] The old heart route, a BMI from 27 with established heart disease and no diabetes, now sits only in the high-cost section that no longer applies to Wegovy.[1] Wegovy’s label covers lowering heart risk in adults with heart disease and obesity or overweight.[13]

## What about sleep apnea and MASH?

Both have their own Kansas criteria. Zepbound for sleep apnea needs an adult with moderate to severe apnea confirmed by an in-lab sleep study (polysomnography) at 15 or more events an hour, and a BMI of at least 30.[4] There is no CPAP requirement. The first approval lasts 12 months, and a renewal needs a 10% weight loss at a year plus a 50% drop in apnea events or a drop of at least 15 an hour.[4] Someone with type 2 diabetes must use the diabetes form of the drug instead.[4][14] Our guide to [Zepbound for sleep apnea](https://glpwatchdog.org/research/zepbound-for-sleep-apnea) covers the trials.

Wegovy for MASH needs an adult with stage F2 or F3 liver scarring, shown by a biopsy or by a liver stiffness scan in a set range, plus one or more metabolic risk factors, for example central obesity, raised blood pressure or high triglycerides.[5] Approvals last 12 months, and a renewal needs a measured improvement, which for Wegovy can be a 5% weight loss.[5] The newer pill Rezdiffra is approved only after 12 months on Wegovy, unless Wegovy cannot be used.[5] Our page on [GLP-1s for MASH](https://glpwatchdog.org/research/glp1-and-fatty-liver-mash) covers the evidence.

## Can a teenager on KanCare get Wegovy?

Yes, from age 12, once BMI reaches the 95th percentile for a child of that age and sex, the same line the label uses for obesity.[1][13] Saxenda is also open from 12, but at the higher bar of 140% of the 95th percentile or a BMI of 40.[1] Zepbound, Foundayo, Wegovy HD and the Wegovy tablets are for adults.[1] Our page on [GLP-1 drugs in teenagers](https://glpwatchdog.org/research/glp1-drugs-in-teenagers) covers the trials in this age group.

## What about Ozempic and Mounjaro for diabetes?

People with type 2 diabetes use the diabetes drugs. On the November 2026 list, Ozempic, Trulicity and Victoza are the preferred GLP-1s, and Rybelsus and Bydureon BCise are non-preferred.[2] Ask your plan how it handles Mounjaro, which we did not find on the list.

## How do you file, and how do you appeal a denial?

Most KanCare members are in a managed care plan, and the state form goes to that plan’s prior authorization line. The form lists Healthy Blue of Kansas (fax 877-941-9901), Sunflower (fax 833-645-2740) and UnitedHealthcare (fax 866-940-7328), plus the state’s own line for fee-for-service members (phone 800-933-6593, fax 800-913-2229).[3]

Plan members first appeal to the plan, within 60 days of the denial notice, and can then ask the state for a fair hearing within the window the federal rules set, at least 90 days after the plan decides.[10][11] For decisions made by the state agency itself, the Kansas manual requires a written hearing request received within 33 days of the date the notice was mailed, and the Office of Administrative Hearings runs those hearings.[9] A strong appeal fills the gap the denial names: a missing baseline weight, a condition that was not documented, or a renewal weigh-in. Our walkthrough of [prior authorization and appeals](https://glpwatchdog.org/research/glp1-prior-authorization-and-appeals) covers what to send, and the [Kansas state page](https://glpwatchdog.org/states/kansas) has the state’s other facts.

## What if KanCare will not pay?

If a request is denied and an appeal fails, the cash route remains, though Lilly’s savings card terms exclude government programs such as Medicaid.[16] In the self-pay prices we track, Novo Nordisk charges $349 a month for most Wegovy pen doses, and Lilly charges $299 for Zepbound at the starting dose, $399 at 5 mg and $449 at 7.5 mg and up when each refill comes within 45 days.[16][17] Check each program’s terms first. Our comparison of [the lowest cash prices for GLP-1s](https://glpwatchdog.org/research/cheapest-glp1-without-insurance) lays out the options.

## Frequently asked questions

### Does Kansas Medicaid cover Wegovy for weight loss?

Yes, with prior authorization. Adults qualify at a BMI of 30, or 27 with a weight-related condition, and teenagers from 12 whose BMI reaches the 95th percentile. Wegovy is a preferred drug on the November 2026 KanCare list, and the first approval lasts 28 weeks.

### Does KanCare cover Zepbound?

Yes, for adults, with prior authorization, at the same BMI lines as Wegovy. Zepbound is also covered for moderate to severe sleep apnea at a BMI of 30 or more under separate criteria. Since 2026 adults no longer have to try Zepbound before Wegovy.

### Does KanCare cover Foundayo?

Yes. Foundayo is a preferred anti-obesity drug for adults, with prior authorization, under the same rules as Wegovy and Zepbound. Clinical prior authorization for it began October 19, 2026.

### What weight loss does KanCare require for a renewal?

For Zepbound, Wegovy or Foundayo, an adult needs to have lost 5% of their starting weight by week 12, or 10% by week 28, and kept it off. Teenagers need a drop of more than 4% in BMI. Sleep apnea and MASH approvals use their own renewal tests.

### What is the deadline to appeal a KanCare denial?

A plan member first appeals to the plan within 60 days of its denial notice, then can request a state fair hearing after the plan decides. For decisions by the state agency, the Kansas manual requires a written request received within 33 days of the notice's mailing date.

## References

1. Kansas Department of Health and Environment, Division of Health Care Finance Criteria for Prior Authorization: Anti-Obesity Medications (AOMs), last reviewed August 19, 2026, updated November 1, 2026. kdhe.ks.gov. 2026. https://www.kdhe.ks.gov/DocumentCenter/View/407/Anti-Obesity-Medications-PDF
2. Kansas Department of Health and Environment, Division of Health Care Finance Kansas Medicaid Preferred Drug List, last updated November 1, 2026. kdhe.ks.gov. 2026. https://www.kdhe.ks.gov/DocumentCenter/View/420/Preferred-Drug-List-PDF
3. Kansas Department of Health and Environment, Division of Health Care Finance Anti-Obesity Medications (AOMs) Prior Authorization Form, revised August 2026. kdhe.ks.gov. 2026. https://www.kdhe.ks.gov/DocumentCenter/View/15513/Anti-Obesity-Medications-PA-Form-PDF
4. Kansas Department of Health and Environment, Division of Health Care Finance Criteria for Prior Authorization: Obstructive Sleep Apnea (OSA) Agents, approved April 16, 2025. kdhe.ks.gov. 2025. https://www.kdhe.ks.gov/DocumentCenter/View/51434/Obstructive-Sleep-Apnea-OSA-Agents-PDF
5. Kansas Department of Health and Environment, Division of Health Care Finance Criteria for Prior Authorization: Metabolic Dysfunction-Associated Steatohepatitis (MASH) Agents, revised January 21, 2026. kdhe.ks.gov. 2026. https://www.kdhe.ks.gov/DocumentCenter/View/51435/Metabolic-Dysfunction-Associated-Steatohepatitis-MASH-Agents-PDF
6. Kansas Medical Assistance Program KMAP General Bulletin 26070: Preferred Drug List Update, effective May 1, 2026 (repost). sunflowerhealthplan.com. 2026. https://www.sunflowerhealthplan.com/newsroom/kmap-26070.html
7. Kansas Medical Assistance Program KMAP General Bulletin 26159: Pharmaceutical Prior Authorization Updates, effective October 19, 2026 (repost). sunflowerhealthplan.com. 2026. https://www.sunflowerhealthplan.com/newsroom/kmap-26159.html
8. Sunflower Health Plan GLP-1 Weight Loss Authorization Requests (provider notice), September 6, 2024. sunflowerhealthplan.com. 2024. https://www.sunflowerhealthplan.com/newsroom/shpbn-2024-036.html
9. Kansas Department of Health and Environment, Division of Health Care Finance KanCare Eligibility Policy Manual, section 1610: Request for a Hearing (July 2026). khap.kdhe.ks.gov. 2026. https://khap.kdhe.ks.gov/KEESM/July_2026_Output/1000/1600/1610-Request-for-a-Hearing.htm
10. Code of Federal Regulations 42 CFR §438.402: Grievance and appeal systems, general requirements. Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/cfr/text/42/438.402
11. Code of Federal Regulations 42 CFR §438.408: Resolution and notification of grievances and appeals. Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/cfr/text/42/438.408
12. Eli Lilly and Company FOUNDAYO (orforglipron) tablets: prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
13. Novo Nordisk WEGOVY (semaglutide) injection and tablets: prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
14. Eli Lilly and Company ZEPBOUND (tirzepatide) injection: prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
15. United States Code 42 U.S.C. §1396r-8: Payment for covered outpatient drugs (Social Security Act §1927). Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/uscode/text/42/1396r-8
16. Eli Lilly and Company Zepbound savings and self-pay options, with card terms. zepbound.lilly.com. 2026. https://zepbound.lilly.com/savings
17. Novo Nordisk Wegovy savings offer. novocare.com. 2026. https://www.novocare.com/obesity/products/wegovy/savings-offer.html

---

Cite as: GLP Watchdog, Nora Bissett, "Does Kansas Medicaid Cover Wegovy? KanCare's Weight-Loss Rules for 2026", published 2026-11-06. https://glpwatchdog.org/research/kansas-medicaid-glp1-coverage

Canonical HTML page: https://glpwatchdog.org/research/kansas-medicaid-glp1-coverage

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.